Want to see SE:ANNX full AI Analyst Report?
Top Page
Annexin Pharmaceuticals AB
(ANNX)
Select Model
Select Model
Rating:48Neutral
Price Target:
kr13.00
▼(-4.76% Downside)
Action:Reiterated
Date:08/24/26
The score is held back primarily by very weak financial performance (no revenue, sizable losses, and persistent cash burn with shrinking equity/assets), indicating high dependence on external funding. Technical indicators provide some offset with modest near-term momentum (positive MACD; price above 20/50-day averages), but longer-term trend signals remain mixed. Valuation is also a drag due to a negative P/E and no dividend yield support.
Positive Factors
Debt-Free Balance Sheet
The absence of reported debt limits interest obligations and reduces leverage-related financial risk. This gives the company greater flexibility to allocate funds toward research and development, although its very small capital base still creates funding concerns.
Negative Factors
No Revenue Generation
The absence of reported revenue confirms that the company remains dependent on development-stage assets rather than commercial operations. This leaves future value highly contingent on clinical progress, regulatory success, and eventual product adoption.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-Free Balance Sheet
The absence of reported debt limits interest obligations and reduces leverage-related financial risk. This gives the company greater flexibility to allocate funds toward research and development, although its very small capital base still creates funding concerns.
Read all positive factors
Annexin Pharmaceuticals AB (ANNX) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr114.64M
Dividend YieldN/A
Average Volume (3M)1.96K
Price to Earnings (P/E)―
Beta (1Y)1.00
Revenue GrowthN/A
EPS Growth13.53%
CountrySE
Employees4
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding8,718,182
10 Day Avg. Volume1,714
30 Day Avg. Volume1,964
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)5.25
Price to Sales (P/S)0.00
P/FCF Ratio-3.54
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Annexin Pharmaceuticals AB Business Overview & Revenue Model
Company Description
Annexin Pharmaceuticals AB (publ), a clinical stage biotechnology company, develops drug candidates for the treatment of various cardiovascular diseases. It develops ANXV, a human recombinant protein and Annexin A5, natural protein that protects a...
How the Company Makes Money
null...
Annexin Pharmaceuticals AB Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
38
Negative
Cash Flow
16
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -48.00K | -48.00K | -193.00K | -193.00K | -193.00K | -192.00K |
| EBITDA | -41.97M | -36.84M | -50.20M | -43.86M | -40.72M | -50.28M |
| Net Income | -42.49M | -36.89M | -50.25M | -44.05M | -40.73M | -52.14M |
Balance Sheet | ||||||
| Total Assets | 7.99M | 30.16M | 19.04M | 26.76M | 36.68M | 52.79M |
| Cash, Cash Equivalents and Short-Term Investments | 5.27M | 27.39M | 16.34M | 21.41M | 31.11M | 49.48M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 5.47M | 5.22M | 5.32M | 7.95M | 6.53M | 6.06M |
| Stockholders Equity | 2.52M | 24.93M | 13.71M | 18.81M | 30.15M | 46.73M |
Cash Flow | ||||||
| Free Cash Flow | -40.65M | -37.05M | -50.23M | -43.40M | -41.16M | -45.02M |
| Operating Cash Flow | -40.52M | -36.92M | -50.23M | -43.40M | -41.16M | -45.02M |
| Investing Cash Flow | -129.00K | -129.00K | 0.00 | 96.00K | -260.00K | 0.00 |
| Financing Cash Flow | -335.00K | 48.11M | 45.15M | 33.61M | 23.06M | 76.37M |
Annexin Pharmaceuticals AB Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | kr548.10M | 2.73 | 77.69% | ― | ― | ― | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
53 Neutral | kr124.76M | -1.21 | -81.76% | ― | 55.24% | 70.00% | |
49 Neutral | kr191.22M | -3.96 | -13.41% | ― | -68.66% | -137.27% | |
48 Neutral | kr114.64M | -2.84 | ― | ― | ― | 13.53% | |
48 Neutral | kr88.62M | -2.44 | -120.70% | ― | -97.37% | 25.28% | |
43 Neutral | kr1.49B | -3.11 | -53.88% | ― | -87.22% | -70.29% |
* General Sector Average
SE:ANNX
Annexin Pharmaceuticals AB
13.30
-11.33
-45.99%
SE:BINV
BioInvent International AB
23.50
-7.55
-24.32%
SE:XBRANE
Xbrane Biopharma AB
9.50
-26.63
-73.70%
SE:BIOVIC.B
Biovica International AB Class B
0.43
-0.24
-35.22%
SE:SPAGO
Spago Nanomedical AB
0.12
-0.07
-39.15%
SE:CANTA
Cantargia AB
1.86
-0.89
-32.42%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.